WionAH. Rx-to-OTC switch: The process and procedures. Drug Information J1985; 19: 119–26.
2.
SollerRW. Outlook for OTC switches. Am Pharm1991; 31: 38–40.
3.
MadhavanSSchondelmeyerSW. Pharmacists' evaluations of nonprescription availability of metaproterenol, cimetidine, ibuprofen, and nystatin. Am J Hosp Pharm1989; 46: 2486–92.
4.
MartinS. Is a third class of drugs in pharmacy's future?Am Pharm1991; 31: 36–8.
5.
TeminP. Cost and benefits in switching drugs from Rx to OTC. J Health Econ1983; 2: 187–205.
6.
PalumboFB. The impact of the Rx to OTC switch on practicing pharmacists. Am Pharm1991; 31: 41–4.
7.
HirschowitzBI. Lessons from the US multicenter trial of ranitidine treatment of duodenal ulcer disease. J Clin Gastroentrol1983: 5 (suppl 1): 115–22.
8.
FeldmanMBurtonME. Histamine2-receptor antagonists: Standard therapy for acid peptic diseases. N Engl J Med1990; 323: 1672–80.
9.
RichterJE. Gastroesophageal reflux: Diagnosis and management. Hosp Pract1992; (Jan 15):59–66.
10.
SpechlerSJ. Choosing the best intervention for gastroesophageal reflux disease. Modern Med1993; 61: 70–85.
FeldmanMMatonPNMcCallumRWMcCarthyDM. Treating ulcers and reflux: What's new?Patient Care1992; 8: 53–72.
13.
OsterGHuseDMDeleaTEColditzGARichterJM. The risks and benefits of an Rx to OTC switch. The case for over the counter H2 blockers. Medical Care1990; 28: 834–52.
14.
SzeinbachSLSmithMC. Gastroesophageal reflux disease. Pharmacists role in patient referrals. Drug Topics1992; 1 (suppl):1–16.
15.
National Center for Health Statistics. Prevalence of selected chronic digestive conditions: United States 1975. PHS 79–1558 (Vital and Health Statistics, series 10 no. 123). US Dept of Health, Education, and Welfare, 1979.
16.
Product information. Mylanta. Wilmington, DE: Stuart Pharmaceuticals, 1993.
AndersenMSchouJS. Adverse reactions to H2-receptor antagonists in Denmark before and after transfer of cimetidine and ranitidine to over the counter status. Pharmacol Toxicol1991; 69: 253–8.
19.
GrantSMLangtryHDBrogdenRN. Ranitidine: An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs1989; 37: 801–70.
20.
GrantSMLangtryHDGoaKL. Famotidine: An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs1989; 38: 551–90.
21.
PriceAHBrogdenRN. Nizatidine: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs1988; 36: 521–39.
22.
NazarioM. The hepatic and renal mechanisms of drug interactions with cimetidine. Drug Intell Clin Pharm1986; 20: 342–8.
23.
DaltonMJPowellJRMessenheimerJAClarkJ. Cimetidine and carbamazepine: A complex drug interaction. Epilepsia1986; 27: 553–558.
24.
PowellRJDonnKH. Histamine H2 antagonist drug interactions in perspective: Mechanistic concepts and clinical implications. Am J Med1984; 77 (suppl 5B):57–84.
25.
BrogdenRNCarmineAAHeelRCSpeightTMAveryGS. Ranitidine: A review of its pharmacology and therapeutic use in peptic ulcer disease and allied diseases. Drugs1982; 24: 267–303.
26.
Campoli-RichardsDMClissoldSP. Famotidine: Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs1986; 32: 197–221.
SomogyiABochnerF. Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. Br J Clin Pharmacol1984; 18: 175–81.
29.
GriffinJWDiPiroJT. Drug interactions: Theory versus practice. Am J Med1984; 77 (suppl 503):85–9.
30.
PetersenH. Over the counter sales of histamine-2 receptor antagonists. Scand J Gastroenterol1988; 155 (suppl):20–2.
